BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-90@catalystbrief.girapphe.com
DTSTAMP:20261117T061557Z
LAST-MODIFIED:20261117T061557Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Jiangsu HengRui Medicine Co.\, Ltd. — SHR-A1811 [Dec 202
 6]
DESCRIPTION:Phase 3 primary completion: A Trial of SHR-A1811versus Pyrotini
 b in Combination With Capecitabine in HER2-Positive\, Unresectable and/or 
 Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and 
 Taxane.\nSource: https://clinicaltrials.gov/study/NCT05424835\nhttps://cat
 alystbrief.girapphe.com/e/90?lang=en\nNot investment advice. Dates may cha
 nge.
URL:https://catalystbrief.girapphe.com/e/90?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
